Submission of Audited Financial Results of Jhonson Pharmacare ltd for the quarter and year ended on March 31st March 2026
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 19 Jun 2026, 06:41 PM IST · BSE ID: 4e3e43e1-dad3-46c3-a57a-fe5d0ec16719
View Original BSE Filing (PDF)
💡
In Simple Terms
Auditors gave a warning about Johnson Pharmacare's yearly financial report due to issues with loans and how investments are valued.
🤖 AI Summary
- Johnson Pharmacare submitted audited financial results for the quarter and year ended March 31, 2026.
- Independent Auditors issued a qualified opinion on the standalone financial statements for FY26.
- Auditors identified borrowed loans of Rs. 2140.04 Lakhs as a key audit matter due to non-provision of interest.
- Company should have prepared financial statements in compliance with IND-AS, which may significantly affect the statements.
- Independent valuation reports for investments in unquoted instruments were not available for auditor consideration.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Borrowed Loans (FY26)
Rs. 2140.04 Lakhs
🏢 How This Affects the Company
The qualified audit opinion and identified issues with borrowed loans of Rs. 2140.04 Lakhs indicate potential adjustments to the financial statements if interest provisions were made and IND-AS applied. The fair valuation of unquoted investments lacked independent reports, impacting the reliability of these asset valuations.
The qualified opinion from auditors increases financial reporting risk due to non-provision of interest on loans and non-compliance with IND-AS. The lack of independent valuation reports for unquoted investments also presents an additional risk regarding asset valuation accuracy.
👥 What This Means For Shareholders
✅
Action Required
No direct action required from shareholders based on this specific filing. Shareholders may review the full audited financial statements and auditor's report.
👤
Who Is Affected
All shareholders of Johnson Pharmacare Limited are affected by the qualified audit opinion as it indicates potential inaccuracies or non-compliance in the company's financial reporting.
🔍
Management Signal
Management presented audited financial results with a qualified opinion, indicating a decision to disclose the auditor's findings without immediate resolution of the identified issues.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Company's response to qualified audit opinion and action plan.
Next quarterly financial results for any improved compliance or resolution.
Any further disclosures regarding IND-AS compliance or valuation of unquoted instruments.
HIGH RISK
Qualified audit opinion indicates material misstatements or non-compliance with accounting standards, affecting financial reliability.
💡 Investor Takeaway
Johnson Pharmacare's FY26 audited financial results received a qualified opinion from auditors. Key concerns include non-provision of interest on Rs. 2140.04 Lakhs borrowed loans and lack of independent valuation reports for unquoted instruments.
⚖️ Strengths & Concerns
⚠️ Concerns
- Auditors issued a qualified opinion on standalone financial statements for FY26, citing non-provision of interest on loans and non-compliance with IND-AS.
- Borrowed loans amounting to Rs. 2140.04 Lakhs were identified as a key audit matter, lacking clear terms and leading to a qualified opinion.
- Independent valuation reports for investments in unquoted instruments were not available for the auditors' consideration.
📅 Company Track Record
Johnson Pharmacare's prior filings on May 27, 2026, also noted the auditors issued a qualified opinion on FY26 results, specifically citing Rs. 2140.04 Lakhs in borrowed loans. This current filing reaffirms the same qualified opinion and the identified issues.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the key issue identified in Johnson Pharmacare's FY26 audit report?
The key issue identified is the balance of borrowed loans amounting to Rs. 2140.04 Lakhs, for which there was non-provision of interest, leading to a qualified audit opinion.
Did auditors provide an unqualified opinion for Johnson Pharmacare's FY26 results?
No, the independent auditors issued a qualified opinion on the standalone financial statements of Johnson Pharmacare Limited for the year ended March 31, 2026.
What was the amount of borrowed loans highlighted as a key audit matter for Johnson Pharmacare?
Borrowed loans amounting to Rs. 2140.04 Lakhs were highlighted as a key audit matter by the auditors for Johnson Pharmacare Limited.
Were independent valuation reports available for Johnson Pharmacare's unquoted investments?
Independent valuation reports for investments in unquoted instruments were not available for the auditors' consideration during the audit process.
What accounting standard compliance issue was noted for Johnson Pharmacare in FY26?
The auditors noted that Johnson Pharmacare should have prepared financial statements in compliance with IND-AS, which may significantly affect the company's financial statements.
Questions based on this BSE filing only. For information purposes.